Exhibit 99.1

NEWS RELEASE
- ------------


Contact:  Bob Cardon, Dynatronics Corp.
          800-874-6251, or 801-568-7000


            FDA GIVES DYNATRONICS GO-AHEAD TO MARKET NEW LASER PROBE

         Salt Lake City, Utah (June 14, 2004) - Dynatronics Corporation (NASDAQ:
DYNT) today announced the U.S. Food and Drug Administration has given marketing
clearance for the company's new Solaris D890 low-power laser probe. The laser
treats muscle and joint pain, including the pain and stiffness associated with
arthritis. The Solaris D890 is the second probe designed for use as an accessory
to the company's popular new Solaris Series products. The probe is expected to
be ready for shipment within 30 to 60 days.
         "We are thrilled with the FDA's decision to allow us to begin marketing
this laser probe," stated Kelvyn H. Cullimore Jr., president of Dynatronics.
"Our first attempt to obtain approval for a laser probe was over 20 years ago.
That makes this clearance even more satisfying."
         According to Larry K. Beardall, Dynatronics' executive vice president
of marketing and sales, "The new D890 probe will expand the foundation of
success our Solaris product line has already achieved. With two decades of
clinical research behind them, lasers have been of keen interest to the medical
community and have found many applications in medical settings. Hundreds of
people around the country have already benefited from light therapy. The results
have been remarkable."
         More information regarding this technology is available at
www.dynatronics.com.
         Dynatronics manufactures, markets and distributes advanced-technology
medical devices, orthopedic soft goods and supplies, treatment tables and
rehabilitation equipment for the physical therapy, sports medicine,
chiropractic, podiatry, plastic surgery, dermatology and other related medical,
cosmetic and aesthetic markets.

         This press release contains forward-looking statements. Those
statements include references to the company's expectations and similar
statements. Actual results may vary from the views expressed in the
forward-looking statements contained in this release. The development and sale
of the company's products are subject to a number of risks and uncertainties,
including, but not limited to, changes in the regulatory environment, FDA
clearance of new products, growth in the physical medicine industry, competitive
factors, availability of third-party component parts and products, inventory
risks due to shifts in market demand, changes in product mix, market demand for
the company's products, increased terrorist activity, and the risk factors
listed from time to time in the company's SEC reports, including, but not
limited to the report on Form 10-KSB for the year ended June 30, 2003 and its
subsequent quarterly reports on Form 10-QSB.
                                                         # # #